Immune-related adverse events (irAEs) are one of the leading causes affecting success rates of immunomodulatory drugs requiring a concerted multistakeholder effort across the drug development process—especially within the nonclinical phase. One of the ways in which the imSAVAR consortium aims to help improve the research and development process and bring a degree of alignment is by creating a Model Grading System through an iterative manner and by leveraging on the imSAVAR Stakeholder Community. A key aspect of the imSAVAR project is continuing dialogue with patient stakeholders to keep the imSAVAR research agenda patient-centred and maximise outcomes for patients. This workshop has been co-designed with three oncology-focused Patient Stakeholder Groups to elucidate inclusion of patient preferences within nonclinical assessment of immunomodulatory therapies and more specifically within the imSAVAR Model Grading System.
Please click here to view the Workshop Programme.
Please click here to register for the Workshop.